Viatris Inc. (VTRS)
Summary
Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris
Cavendish has reiterated its buy rating on Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) following the pharmaceutical company's agreement to take full commercial control of its main United States (US) product from Viatris. The broker kept its target price at 23 pence, implying potential upside of 318% from current share price of about 5.5 pence.
Here's Why Viatris (VTRS) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Viatris Inc. (VTRS) Q2 2026 Earnings Call Transcript
Viatris Inc. (VTRS) Q2 2026 Earnings Call Transcript
Viatris Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| DI David Izzi Brown, LISLE/CUMMINGS Inc. | 800 | $9,250 | $14,048 | $4,798 | 51.87% |
 Timothy M. Bidwell Hazlett, BURT & WATSON Inc. | 5,949 | $64,725.12 | $104,464.44 | $39,739.32 | 61.4% |
| LC Lisa Candera CIGNA INVESTMENTS Inc. /NEW | 10,693 | $193,147.46 | $187,769.08 | -$5,378.38 | -2.78% |
 Curtis Ellergodt Rothschild Investment LLC | 17,709 | $192,187.14 | $313,449.3 | $121,262.16 | 63.1% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 174,057 | $2.76M | $2.86M | $95,722.51 | 3.46% |
Viatris Inc. (VTRS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Viatris Inc. ever had a stock split?
Viatris Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Scott Andrew Smith CEO | NASDAQ (NGS) Exchange | 92556V106 CUSIP |
| US Country | 30,000 Employees | 21 Aug 2026 Last Dividend | 9 Oct 2003 Last Split | 16 Nov 2020 IPO Date |
Overview
Viatris Inc. is a global healthcare company that has marked its presence worldwide since its foundation in 1961, with its headquarters situated in Canonsburg, Pennsylvania. The company operates across various segments globally, including Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. Viatris is committed to providing access to medicines, sustainable operations, and community support, focusing on addressing the needs of patients in both noncommunicable and infectious disease domains. Its wide array of products stretches from prescription brand drugs to complex generics, biosimilars, and active pharmaceutical ingredients (APIs), catering to a broad spectrum of therapeutic areas and underpinning its mission to empower people worldwide to live healthier at every stage of life.
Products and Services
Viatris Inc.'s expansive portfolio encompasses a diverse range of healthcare solutions, from critical medicines to comprehensive support services, aimed at enhancing patient care and access:
- Prescription Brand Drugs & Generics: Includes essential medications for various health conditions, ensuring patients have access to quality treatment options.
- Complex Generic Drugs: Offers complex generics that are equivalent to brand-name drugs, providing more accessible and cost-effective treatment alternatives.
- Biosimilars: The company produces biosimilars for oncology, immunology, endocrinology, ophthalmology, and dermatology, offering high-quality alternatives to existing biologic drugs.
- Active Pharmaceutical Ingredients (APIs): APIs for a vast range of therapeutic areas including antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors, highlighting the breadth of Viatris’s capabilities in drug manufacturing.
- Support Services: Beyond just providing medications, Viatris also facilitates diagnostic clinics, educational seminars, and digital tools to help individuals better manage their health, emphasizing the holistic approach to healthcare.
Medications are delivered in various forms, including oral solid doses, injectables, and complex dosage forms, ensuring versatility in administration ways to suit different patient needs. Distribution channels encompass pharmaceutical wholesalers/distributors, retailers, institutional pharmacies, mail-order, e-commerce, and specialty pharmacies, ensuring broad accessibility. Products like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, and the EpiPen auto-injector, among others, highlight the wide range and significance of Viatris’s offering in addressing global health issues. Through partnerships, like with Revance Therapeutics, Inc. and Momenta Pharmaceuticals, Inc., Viatris Inc. continues to expand its portfolio, promising innovation and expanded access to essential medicines for patients worldwide.
